Look Under The Hood: IHE Has 24% Upside

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Pharmaceuticals ETF ( IHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $183.23 per unit.

10 ETFs With Most Upside To Analyst Targets »

With IHE trading at a recent price near $148.14 per unit, that means that analysts see 23.69% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IHE's underlying holdings with notable upside to their analyst target prices are Merrimack Pharmaceuticals Inc. ( MACK), Amicus Therapeutics Inc ( FOLD), and Dermira Inc ( DERM). Although MACK has traded at a recent price of $6.26/share, the average analyst target is 43.77% higher at $9.00/share. Similarly, FOLD has 42.85% upside from the recent share price of $9.20 if the average analyst target price of $13.14/share is reached, and analysts on average are expecting DERM to reach a target price of $44.33/share, which is 26.13% above the recent price of $35.15. Below is a twelve month price history chart comparing the stock performance of MACK, FOLD, and DERM:

MACK, FOLD, and DERM Relative Performance Chart

Below is a summary table of the current analyst target prices discussed above:

Name Symbol Recent Price Avg. Analyst 12-Mo. Target % Upside to Target
iShares U.S. Pharmaceuticals ETF IHE $148.14 $183.23 23.69%
Merrimack Pharmaceuticals Inc. MACK $6.26 $9.00 43.77%
Amicus Therapeutics Inc FOLD $9.20 $13.14 42.85%
Dermira Inc DERM $35.15 $44.33 26.13%

Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.

If you liked this article you might like

How to Play Pfizer's Fourth-Quarter Results With ETFs

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

3 ETFs to Buy if You Think Pfizer Will Beat Earnings

Biotech Leads the Way in Health Care Stocks to Boost 401(k) Returns

12 Best Biotech and Health Care ETFs to Add to Your Portfolio